Therapeutic Modality of Datopotamab Deruxtecan: A Comprehensive Overview

Abstract

A recently licensed antibody-drug conjugate (ADC) called Datopotamab deruxtecan (Dato-Dxd), or DATROWAY, is used to treat breast cancer that is HER2 negative and has metastasized hormone receptor (HR) positivity. A humanized anti-TROP2 IgG1 monoclonal antibody, a topoisomerase-1 inhibitor payload, and a tetrapeptide-based cleavable linker make up the TROP-2 directed ADC Dato-Dxd. The medication releases the payload and kills cancer cells via binding to the TROP2 surface receptor protein, which is overexpressed in cancer cells. This drug has emerged as a valuable treatment option for the patients with Triple-Negative Breast Cancer (TNBC). The TROPION-Breast01 phase-3 study, which showed a 37% decrease in disease progression or mortality as compared to chemotherapy in patients with HR-positive, HER-2 negative metastatic breast cancer, served as the basis for the FDA's approval of Dato-Dxd. When providing this medication to the elderly and those with co-existing diseases, great care must be given. Pregnant women should not use this medication since it might have negative effects on the foetus and cause adverse effects like alopecia, stomatitis, and interstitial lung disease. Dato-Dxd is a promising new treatment option for individuals with advanced breast cancer, despite its drawback. The use of this medication in combination therapy with PARP inhibitors to treat cancers is being investigated in ongoing clinical trials.